Brokerages Set Immunocore Holdings plc (NASDAQ:IMCR) Price Target at $65.64

Immunocore Holdings plc (NASDAQ:IMCR) has been given an average rating of “Moderate Buy” by the thirteen analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $65.64.

IMCR has been the topic of several recent analyst reports. Needham & Company LLC reduced their price objective on shares of Immunocore from $78.00 to $71.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Morgan Stanley reissued an “equal weight” rating and issued a $35.00 price target (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. Mizuho cut shares of Immunocore from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $72.00 to $38.00 in a research report on Monday, November 11th. UBS Group started coverage on Immunocore in a research report on Thursday, October 24th. They issued a “sell” rating and a $24.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research report on Thursday, October 24th.

Hedge Funds Weigh In On Immunocore

A number of hedge funds and other institutional investors have recently bought and sold shares of IMCR. Envestnet Asset Management Inc. lifted its holdings in Immunocore by 0.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 70,571 shares of the company’s stock worth $2,392,000 after purchasing an additional 606 shares during the last quarter. Pier Capital LLC increased its position in Immunocore by 1.4% during the 3rd quarter. Pier Capital LLC now owns 82,480 shares of the company’s stock worth $2,568,000 after buying an additional 1,174 shares during the period. Exchange Traded Concepts LLC lifted its holdings in shares of Immunocore by 40.4% during the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after buying an additional 1,461 shares in the last quarter. Assetmark Inc. boosted its position in shares of Immunocore by 6.5% in the third quarter. Assetmark Inc. now owns 30,555 shares of the company’s stock valued at $951,000 after acquiring an additional 1,878 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Immunocore by 69.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock valued at $231,000 after acquiring an additional 3,053 shares in the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Performance

IMCR stock opened at $30.23 on Friday. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. Immunocore has a twelve month low of $27.69 and a twelve month high of $76.98. The business’s fifty day moving average is $31.19 and its 200-day moving average is $33.80. The company has a market cap of $1.51 billion, a P/E ratio of -31.82 and a beta of 0.76.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.50. The firm had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company’s quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.59) earnings per share. Equities research analysts forecast that Immunocore will post -0.94 EPS for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.